Document:

Exhibit 10.13

 

MASTER SERVICES AGREEMENT

 

This Master Services Agreement
(the “Agreement”) is entered into as of April 27th, 2015 (the “Effective Date”) by and between Accelerated
Pharma Inc. with a place of business at 15W15581st, Burr Ridge 60527 Illinois, USA (“Accelerated”),
and Heraeus Precious Metals GmbH & Co. KG, a German limited liability company with a principal place of business located
at Heraeusstr. 12- 14, 63450 Hanau, Germany (“Manufacturer” or “Heraeus”), each singly a “Party”
and together, the “Parties.”

 

RECITALS

 

Accelerated intends to entrust Heraeus with
the manufacture of the active pharmaceutical ingredient Picoplatin which is required by Accelerated for a clinical development
program.

 

NOW, THEREFORE, the Parties agree as follows:

 

AGREEMENT

 

1             DEFINITIONS.
Throughout this Agreement, the following terms will be defined thus:

 

		1.1	“Affiliates” means any company, firm, individual,
partnership or other legal entity which controls, or is controlled by, or controlled in common with a Party. “Control”
here means holding more than 50% of the nominal value of the issued share capital or of the voting power at the general meeting
of shareholders or members or has the power to appoint a majority of the directors or otherwise directs the activities of such
company, firm, partnership or other legal entity.

 

		1.2	“Confidential Information” is defined in Section
6 below.

 

		1.3	“Day” or “Days” means a calendar
day or days. “Business Days” are weekdays, excepting legal holidays and local holidays in Germany and/or Hessen.

 

		1.4	“Order” means a purchase order for the Products
and services, as further described below, pursuant to this Agreement.

 

		1.5	“Person” means any individual, partnership,
company, firm, legal entity, trust, trustee or association.

 

		1.6	“Personnel” means the employees of a Party,
individuals working as subcontractors of a Party, and employees of such Party’s affiliates, contractors and agents.

 

		1.7	“Product” means the active pharmaceutical ingredient
Picoplatin as described in Annex 1. 1.8 “Specifications” means the technical criteria described in Annex 1.

 

		1.9	Other definitions are found within the Agreement next to
the term defined.

 

2.            SERVICES

 

Manufacturer will provide Services and Products according to Order(s)
made from time to time by both Parties in writing. The Initial Services are described in Annex 1. Each Order, confirmed by the
Manufacturer in writing, executed pursuant to this Agreement shall form a separate agreement between the Parties and be governed
by the terms of this Agreement as if contained therein in their entirety. In the event of any conflict between the terms of this
Agreement and any particular Order, the terms of this Agreement shall take precedence.

 

    	 	 	 

     

    

 

2.1          Manufacturing Services. By signing
this Agreement, Heraeus is entrusted to manufacture three (3) validation batches under CGMP conditions and to deliver these batches
to Accelerated for their clinical development program. A validation batch contains at least 500g of the Product. If Accelerated
requires further validation batches, Accelerated may order further validation batches or GMP batches of the Product at a later
point in time. Each batch shall consist of a minimum quantity of 500g. By signing this Agreement, Heraeus is also entrusted to
create a GMP documentation as well as to conduct a stability study for the Product.

 

2.2          Shipping, Title and Risk of Loss.
The Products will be shipped, Ex Works per Incoterms the Manufacturer’s loading dock, such that title to and risk of loss
in all Product will pass to the Accelerated at the point of shipment using the Accelerated’ s carrier account noted on the
Order. Orders shall be shipped at a mutually agreed upon date and time. After written notice from Accelerated, Manufacturer will
promptly ship the quantities of any missing Product to remedy any shortage.

 

2.3          Delivery. Manufacturer will ensure
Products are packaged sufficiently to maintain their integrity during transportation.

 

2.4          Acceptance. Products will be
deemed accepted upon delivery unless Accelerated makes a rejection of the Products within thirty (30) days of arrival at Accelerated’
s designated destination. Claims for shortages, damage, or obvious defects must be made in writing within that time period. Accelerated
shall not unreasonably reject Products that conform to specifications.

 

2.5          Title. Title and risk of loss
to the Products shall pass to Accelerated at the time Products are delivered to Accelerated. However, Manufacturer retains a security
interest on Products until payment in accordance with this Agreement.

 

2.6          Additional Services. Parties
may agree to contract for additional services than those described in 2.1. Such agreement will be pursuant to a request for quote
(“Request for Quote”) provided by Accelerated to Manufacturer. The Request for Quote will provide sufficient detail
to allow the Manufacturer to proceed with each individual manufacturing project, including details on validation protocols, Accelerated’
s production needs and forecasts, if any, and other details as provided.

 

2.7          Additional Terms. Additional
terms pertaining to shipment of products, delays, risk of loss, insurance, and other terms not provided in this Agreement will
be according to Manufacturer’s terms and conditions of sale (The “Heraeus Terms and Conditions of Sale”), as
then in effect. (The current terms are specified in Annex 2) If there is a conflict between the Agreement and the Heraeus Terms
and Conditions of Sale, then this Agreement will govern.

 

3.            PRICING AND PAYMENT

 

3.1          Pricing for Initial Services
are described in Annex I. The prices for Products ordered by Accelerated at a later point in time are set forth in Heraeus’
offer which Heraeus will send to Accelerated, if and when required. The prices to be paid to Heraeus are exclusive of any statutory
value-added tax as well as exclusive of any other taxes, Pricing duties and charges.

 

    Page 2 of 10 

     

    

 

3.2          If not agreed otherwise agreed
in writing Payment terms for products and services will be Net 30 days after the date of invoice or date of delivery, whichever
occurs later. Invoicing requirements, if any, will be as specified in a mutually agreed electronic format, or if there is no such
format, in the applicable Order.

 

4.            QUALITY

 

4.1          Product Changes

 

4.1.1      Accelerated Proposed Product Changes.
Accelerated may propose changes to any of the Products by submitting such changes to Manufacturer. Accelerated will identify those
changes that it deems mandatory in order to make the Product suitable for Accelerated’s intended use. Unless otherwise agreed
to in writing by Accelerated, Manufacturer will respond in writing to Accelerated within ten (10) Days after receipt of such proposed
or mandatory changes with the following information, as applicable: (i) lead time required to implement the changes, provided that
it is technically feasible; (ii) impact of changes on Product, including, but not limited to, any Parts, tooling, and testing,
and additional costs; (iii) impact of changes on scrap material and work in process; (iv) any non-recurring engineering changes
required in order to implement the changes; and (v) impact of changes on the lead time of the Product.

 

4.1.2      Manufacturer Proposed Product Changes.
Any changes proposed by Manufacturer, including material or process changes, which affect form, fit, function, reliability, serviceability,
performance, functional interchange-ability, regulatory compliance, safety, must be submitted along with a written change notice,
for Accelerated approval. This may include, but is not limited to, changes of sources of material and parts, changes in accepted
manufacturing range, manufacturing processes, test procedures, or replacement of equipment. No such changes may be implemented
by Manufacturer without receiving Accelerated’s prior written approval.

 

4.2          Quality Management System.

 

4.2.1       Manufacturer shall document, implement,
and maintain an acceptable Quality System. Manufacturer will test and inspect all Products in accordance with its existing procedures
before shipping any Products to Accelerated. Manufacturer will supply an Accelerated -approved certificate of compliance for all
Products shipped, which includes the results of the standard testing and procedures. Manufacturer will document all of its standard
operating procedures, including quality assurance, manufacturing, testing and delivery and make copies of those procedures available
to Accelerated for its review and audit.

 

4.2.3       In the event that any Product
fails to meet the specifications, whether discovered prior to delivery or after, Manufacturer will investigate such failure and
document the nature and root cause of the failure. Manufacturer will devise proposed changes to its processes and procedures as
needed in order to avoid repetition of known failures.

 

    Page 3 of 10 

     

    

 

5.            CONFIDENTIALITY

 

5.1          Disclosure and Use of Confidential
Information. In the course of performing or receiving Services in connection with this Agreement, the Manufacturer or Accelerated
(each, when receiving information, the “Receiving Party”) may be given or have access to, confidential and proprietary
information as defined as Confidential Information of the other Party below (the “Disclosing Party”). The Disclosing
Party’s affiliates, subsidiaries, independent contractors, business partners, and licensors, may disclose information relating
to any or all of the Disclosing Party’s products and/or services (whether marketed or in development), business proposals,
manufacturing and distribution processes, customer lists, computer software and related documentation, financial information, and
employee data, whether tangible or intangible, and including all copies, analyses and derivatives thereof, that is marked or otherwise
identified as proprietary or confidential at the time of disclosure, or which if disclosed orally is confirmed in writing by the
Disclosing Party to the Receiving Party within thirty (30) days of initial disclosure (collectively, “Confidential Information”).
The Receiving Party shall not, without the Disclosing Party’s prior written consent, disclose to any third-party any Confidential
Information or use any Confidential Information for any purpose other than performance of the Services. The Receiving Party shall
employ the same standard of care in protecting disclosed Confidential Information as it would employ to protect its own confidential
information, but shall in no event use less than reasonable care. The Receiving Party shall disseminate Confidential Information
to its personnel and Suppliers only on a “need-to-know” basis. The Receiving Party shall cause each of its personnel
and Suppliers who have access to Confidential Information to comply with the terms of this Section 6 in the same manner
as it is bound by this Section 6, with the Receiving Party remaining responsible for the actions and disclosures of any
such personnel.

 

5.2          Exceptions to Confidential Information.
For purposes hereof, “Confidential Information” does not include information that (i) was rightfully in the Receiving
Party’s possession without restriction before disclosure hereunder, (ii) was or becomes public knowledge through no fault
of the Receiving Party, (iii) was rightfully disclosed to the Receiving Party without restriction by a third-party not bound by
a confidentiality restriction, or (iv) was independently developed by the Receiving Party or its personnel. The restrictions in
this Section 6 shall not prevent disclosures required by law, court order or other governmental order or demand; provided
that, to the extent practicable, the Receiving Party provides prompt written notice and reasonable assistance to the Disclosing
Party prior to such disclosure, so that the Disclosing Party may seek a protective order or other appropriate remedy to protect
against or limit such disclosure. The confidentiality obligations set forth in this Agreement shall expire five (5) years from
the date of the disclosure.

 

6.            REPRESENTATIONS

 

6.1          Compliance with Laws. Manufacturer
represents and warrants that Manufacturer shall comply with all applicable laws and regulations and customer policies in which
the Services will be provided, including the maintenance of necessary government permits, licenses and other means by which to
lawfully perform Services. Manufacturer further represents and warrants that no action (or failure to take action) by it or any
of its employees will cause Accelerated to violate or incur any penalty under any applicable law or regulations. Manufacturer does
not assume any liability for the non-infringement of any third-party rights by the manufacture, the placing on the market or the
use of the Product. It shall be the sole responsibility of Accelerated to perform a Freedom to Operate Analysis to ensure that
the Product in the application intended by Accelerated does not infringe any third-party rights.

 

6.2          No Other Restrictive Arrangement.
Manufacturer is not subject to, or a party to, any employment agreement, non-competition covenant, non-disclosure agreement, or
other agreement, covenant, understanding, or restriction that would prohibit Manufacturer from executing this Agreement and performing
fully the duties and responsibilities hereunder.

 

6.3          Disclosure. A Party shall within
three (3) calendar days notify the other Party in the event any representation or warranty by the Party set forth in this Agreement
shall no longer be true, correct, or complete.

 

    Page 4 of 10 

     

    

 

6.4          Conflict
of Interest. Manufacturer covenants that, during the term of this Agreement, Manufacturer will not engage, directly or
indirectly, in any activity that materially conflicts with Manufacturer’s faithful performance of the Services.

 

6.5          Representations and Indemnifications
of Accelerated. Accelerated represents and warrants that Accelerated has all IP rights required for the manufacture, the placement
on the market and the use of the Product in the application intended by Accelerated. In addition, Accelerated represents and warrants
that Accelerated rightfully acquired any and all rights to the manufacturing process of the Product from Poniard Inc. and that
Accelerated is entitled to exercise these IP rights. Accelerated will, upon first written request, indemnify and hold Manufacturer
harmless from and against any and all claims which are asserted or entered against Manufacturer by any third party on account of
the alleged or actual infringement of third party IP rights by the manufacture and/or delivery and/or use of the Product in pharmaceutical
products of Accelerated or third parties. Accelerated shall reimburse to Heraeus any and all damages accruing to Heraeus on account
of such alleged or actual infringement of third-party property rights by the manufacture and/or delivery to Accelerated.

 

7.            WARRANTY AND LIABILITY

 

7.1          Warranty

 

7.1.1       Limited Warranty. Manufacturer
warrants that the Products will be free from defects in workmanship and materials and will conform to the specifications set forth
in Annex 1 for a period of ninety (90) days from the date of receipt by Accelerated (the “warranty period”).

 

7.1.2       Subject to Section 5.1.4,
the Manufacturer’s responsibility for defective or non-conforming Products is limited, at Manufacturer’s option,
to either replacement of the defective Products or return to Accelerated of monies actually
received by Manufacturer from Accelerated for those defective Products, less any unrecoverable costs for components or sub-assemblies.
Manufacturer may require inspection of the defective or non-conforming Products. However, no Product may be returned to Manufacturer
unless such returned Product shall first have been determined to be defective or non-conforming.

 

7.1.3       Accelerated will pay Manufacturer
the cost of all charges, including but not limited to a reasonable charge for examination and rework if the returned Products
prove not to be defective or for work requested by Accelerated that exceeds Manufacturer obligations under this Warranty.

 

7.1.4       This Warranty extends only to
the original customer of the Products (that is, Accelerated). This Warranty does not apply to, and Manufacturer assumes no responsibility
for, damage or defects due to any cause other than those specified above, including, but not limited to, damage or defects arising
as a result of misuse, improper installation by Accelerated’s personnel or subcontractors, accident, neglect, modification,
repair by Accelerated, adverse conditions, and demands exceeding performance levels required by applicable specifications by Manufacturer.
Provision of Products to any third-party terminates this warranty, even though the warranty period has not expired, unless tests
Products against specifications using tests or methods acceptable to Manufacturer prior to that incorporation. In no case, however,
shall the warranty extend beyond the 90-day warranty period.

 

    Page 5 of 10 

     

    

 

7.1.5       THIS
WARRANTY IS EXCLUSIVE AND MADE IN LIEU OF ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. NO MODIFICATION OR ALTERATION OF THE FOREGOING WARRANTY AND LIMITATION
OR REMEDIES PROVISIONS SHALL BE VALD OR ENFORCEABLE UNLESS SET FORTH IN A WRITTEN AGREEMENT SIGNED BY HERAEUS AND THE
CUSTOMER.

 

8.            LIMITATION OF LIABILITY. EXCEPT IN
THE CASE OF BREACH OF CONFIDENTIALITY, IN NO EVENT SHALL EITHER PARTY OR ITS EMPLOYEES, AGENTS, AFFILIATES, OWNERS OR OFFICERS
BE LIABLE TO THE OTHER PARTY FOR SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, PUNITIVE OR EXEMPLARY DAMAGES, HOWEVER CAUSED, WHETHER
FOR BREACH OF WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE.

 

9.           INDEMNIFICATION

 

9.1          Indemnification by Accelerated.
Accelerated shall indemnify, defend and hold harmless Manufacturer, its Affiliates, and their respective officers, directors, agents,
employees, and shareholders from and against all claims whether such claim is stated as a product liability claim, a strict liability
claim or other similar claims, to the extent such claims on any legal theory relates to or arises from: (a) personal injury or
death of any person from any pharmaceutical product manufactured or sold by Accelerated that incorporates a Product, provided that
this indemnification obligation shall not extend to a claim to the extent such claim is found to have been directly caused by Manufacturer’s
negligence, gross negligence or willful misconduct, or violation of any material applicable local, state, federal, foreign or international
law or regulation, in each case in connection with the manufacture, labeling, packaging, sale, storage or shipment of such Product,
as proven by a final non-appealable judgment, (b) the infringement or alleged infringement of any third-party’s patent, copyright
or trade secret right to the extent such infringement is based upon Accelerated’ s specifications or the design of the products
provided by Accelerated to Manufacturer or the end use or application of a product, or (c) Accelerated’ s negligence, gross
negligence or willful misconduct, or violation of any material applicable local, state, federal, foreign or international law or
regulation, in each case in connection with the manufacture, assembly, design, handling, labeling, packaging, sale, storage or
shipment of devices incorporating any Product, as proven by a final non-appealable judgment. Manufacturer shall: (i) give Accelerated
prompt written notice of any claims for which Manufacturer may seek indemnification from Accelerated; (ii) permit Accelerated to
participate in the defense of the same through its counsel, subject to any applicable privileges; (iii) give relevant information
in its possession relating to such claims; (iv) assist in such defense; and (v) not compromise or settle any such claims without
Accelerated’s written consent.

 

9.2          Insurance provided by Accelerated.
For the clinical development project, Accelerated is obligated to take out an insurance for the test persons which provides sufficient
coverage in the event any test person suffers injuries to life, body or health. Accelerated will include Heraeus as additional
insured under this insurance policy.

 

10.          TERM

 

This Agreement shall commence on the Effective
Date and will continue in full force and effect until completion of the Services, unless terminated as provided in Section 13.

 

11.          TERMINATION AND POST-TERMINATION
OBLIGATIONS

 

11.1       Termination by Mutual Consent.
This Agreement may be terminated at any time by mutual written agreement of the Parties.

 

    Page 6 of 10 

     

    

 

11.2        Optional Termination. This Agreement
may be terminated by either of the Parties without cause by giving the other Party fifteen (15) calendar days’ prior written
notice.

 

11.3        Termination by Accelerated. Accelerated
may terminate this Agreement, effective immediately upon written notice to Manufacturer, in the event of a material breach of this
Agreement (including the breach of any of the representations and warranties contained herein), bankruptcy, loss of commercial
registration or cessation of business, except that in the event of a breach caused by Product quality issues, Accelerated will
provide Manufacturer with notice and a reasonable opportunity to cure by repair or replacement of non-conforming Products with
conforming Products.

 

11.4        Effect of Termination. On termination,
Accelerated’s sole obligation to Manufacturer will be to pay any then-outstanding unpaid fee for Services actually performed
hereunder and to reimburse Manufacturer for then-outstanding reimbursable expense. Manufacturer shall waive any and have no claims
upon Accelerated in respect of any severance or similar compensation in any form. Manufacturer hereby expressly agrees that termination
of this Agreement will not void, invalidate, or otherwise affect Manufacturer’s obligations under Section 6 (Confidentiality).
Manufacturer expressly agrees that the terms of Section 6 will survive expiration or termination of this Agreement.

 

12.          NOTICE TO ACCELERATED

 

12.1        If Manufacturer receives a request
or demand to disclose any books, documents, or records relevant to this Agreement for the purpose of an audit or investigation,
Manufacturer shall notify Accelerated immediately (within two (2) business days after receipt of such request or demand) in writing
of the nature and scope of such request or demand. Manufacturer shall make available to Accelerated, upon written request of Accelerated,
all such books, documents, or records.

 

13.          MANUFACTURER PERSONNEL

 

13.1 Manufacturer shall be solely responsible
for the compensation of its Personnel, including the payment of salary, benefits and employment-related taxes and withholding.
Manufacturer shall be permitted to use subcontractors to provide Services under this Agreement.

 

14.          INTELLECTUAL PROPERTY

 

14.1       Accelerated Intellectual Property.
Manufacturer acknowledges (a) Accelerated’s exclusive right, title and interest in and to Accelerated’s Intellectual
Property; (b) the validity of any and all registrations thereof; (c) that Accelerated is the sole owner of same and all goodwill
relating thereto; and (d) that Manufacturer shall not, by reason of this Agreement or otherwise, acquire any right title or other
ownership therein other than the limited privilege of use contemplated by this Agreement. For these purposes, -Intellectual
Property” means that all trademarks and foreign language equivalents, copyrights and translations of Accelerated copyrights
property, domain names, trademarks and trade names, patents, trade dress, emblems, designs (whether registered or not), insignia,
models and methods of Accelerate, Accelerated’ s Confidential Information and any other intellectual property relating to
Accelerated’ s products or packaging, labeling, advertising and promotional materials used for and/or relating to such products.
Manufacturer agrees that he shall take no steps to challenge or impair Accelerated’s Intellectual Property. Subject to these
restrictions and upon prior written approval by Accelerated of content and format, Manufacturer may indicate on its stationery,
advertising and promotional materials that it is Accelerated’s supplier.

 

    Page 7 of 10 

     

    

 

14.2        Manufacturer Intellectual Property.

 

Accelerated acknowledges that, except as specifically
set forth herein, that all right, title and interest in and to Manufacturer’s Intellectual Property shall be solely and exclusively
vested in Manufacturer and no ownership, interest, right or license is granted to the other Party.

 

15.          GOVERNING LAW AND ARBITRATION

 

15.1        Governing Law. This Agreement will
be governed by and construed in accordance with the substantive laws of Germany without regard to its conflict of law rules.

 

15.2        Emergency Remedies. Notwithstanding
Section 17.2, the Parties acknowledge and agree that that they will have injunctive and other equitable remedies as described
in Section 18.9  (Remedies) below.

 

16.          MISCELLANEOUS

 

16.1       Force Majeure. If the performance
of any obligation under this Agreement by Manufacturer is prevented, restricted, or interfered with by reason of war, revolution,
civil commotion, acts of public enemies, blockade, embargo, strikes, interruption of supply, any law, order, proclamation, regulation,
ordinance, demand, or requirement having a legal effect of any government or any judicial authority or representative of any such
government, which is beyond the reasonable control of the Party affected, then the Party so affected shall, upon giving prior written
notice to the other Party, be excused from such performance (other than the obligation to pay amounts due hereunder) to the extent
of such prevention, restriction, or interference, provided that the Party so affected shall use reasonable commercial efforts to
avoid or remove such causes of nonperformance and shall continue performance hereunder with reasonable dispatch whenever such causes
are removed. Neither Party shall be in default if any delay or failure to perform any obligation hereunder (other than the obligation
to pay amounts due hereunder) that is caused by events beyond such Party’s reasonable control.

 

16.2       Waiver of Compliance. Neither party
shall by mere lapse of time, without giving notice or taking other action hereunder, be deemed to have waived any breach by the
other party of any of the provisions of this Agreement. Further, the waiver by either party of a particular breach of this Agreement
by the other shall not be construed as or constitute a continuing waiver of such breach or of other breaches of the same or other
provisions of this Agreement.

 

16.3       Severability. It is intended that
this Agreement shall not violate any applicable law and the unenforceability or invalidity of any provision, or part thereof, (other
than the provisions obligating Accelerated to make payments to Manufacturer) shall not affect the force and validity of any other
provision and such invalid provisions shall be deemed severed from this Agreement, and, if permissible, be replaced with terms
which as closely as possible approximate the intent of such invalid provisions.

 

16.4       Counterparts. This Agreement may
be executed in any number of counterparts, including electronic or facsimile produced copy, each of which shall be deemed an original
and all of which shall constitute one and the same agreement.

 

16.5       Headings. The headings contained
in this Agreement are for convenience of reference only and do not qualify or affect in any way the meaning or interpretation of
this Agreement.

 

16.6       Construction of Agreement. Each
Party represents that it has carefully read and fully understands the scope and effect of all the provisions of this Agreement,
and that it was offered such period as it deemed necessary to consider it. Consequently, any language deemed to be ambiguous contained
herein shall not be construed in favor of one Party over the other.

 

    Page 8 of 10 

     

    

 

16.7       Relationship. Notwithstanding any
provision hereof, for all purposes of this Agreement each Party shall be and act as an independent contractor and not as partner,
joint venturer, employer, employee or agent of the other and shall not bind nor attempt to bind the other to any contract. Manufacturer
is an independent contractor and is solely responsible for all taxes, withholdings, and other statutory or contractual obligations
of any sort, including, but not limited to, Workers’ Compensation Insurance.

 

16.8       Non-assignment. This Agreement
is personal to Manufacturer and cannot be assigned by Manufacturer or otherwise transferred to any other person or party without
Accelerated’s prior written consent, unless as a part of a sale or transfer of assets to any Manufacturer affiliate. Any
assignment without such consent will be cause for immediate termination of this Agreement by Accelerated. Any other attempts to
transfer will be void. Manufacturer further agrees not to subcontract services under this Agreement, in whole or in part, without
Accelerated’s prior written consent. Manufacturer’s obligations under this Agreement are binding on Manufacturer’s
heirs, legal representatives, administrators, and executors.

 

16.9       Remedies. Notwithstanding and as
an exception to Section17.2 above, the Parties acknowledge and agree that in the event of any breach or threatened breach of Section
6 or the breach of its obligations relating to ownership or use of intellectual property, the other Party will suffer irreparable
damage for which it will have no adequate remedy at law. Accordingly, each Party shall be entitled to seek injunctive and other
equitable remedies to prevent or restrain, temporarily or permanently, such breach or threatened breach, without the necessity
of posting any bond or surety, in addition to any other remedy that such Party may have at law or in equity.

 

16.10     Notices. Notices or communications
to be given under this Agreement shall be provided to the appropriate Party in writing either by personal delivery, overnight delivery
service, confirmed telefacsimile, electronic mail or registered or certified mail, postage prepaid, to the addresses first set
forth above or to such other addresses and to such other persons as either Party may from time to time designate by notice given
as herein provided. Such notices or communications shall be deemed to have been given upon receipt if by personal delivery, five
(5) business days after deposit in the United States mail if sent by first class, registered, or certified mail, postage prepaid,
one (1) business day after delivery if by an overnight delivery service, or upon transmission confirmation if by telefacsimile
or electronic mail.

 

16.11     Entire Agreement. The Parties
hereto acknowledge that this Agreement, together with any Statements of Work attached hereto or executed after the date hereof,
is the complete and exclusive statement of agreement respecting the subject matter hereof and supersedes and renders null and void
any and all agreements and proposals (oral or written), understandings, representations, conditions, and other communications between
the Parties relating hereto and shall constitute the only valid binding and enforceable agreement between them. This Agreement
may be amended only by a subsequent writing that specifically refers to this Agreement. An exchange of email correspondence in
which both Parties agree to a change or addition to the Agreement shall be treated as an agreement in writing for these purposes.

 

    Page 9 of 10 

     

    

 

IN WITNESSETH WHEREOF, the Parties have executed
this Agreement as of the Effective Date.

 

	ACCELERATED
    PHARMA, INC.	 	HERAEUS
PRECIOUS METALS GMBH & Co. KG
	 	 	 	 	 
	By:	/s/
    Michael Fonstein	 	By:	/s/
    Dr. Marcus Hannakam
	Name:	Michael Fonstein	 	Name:	Dr. Marcus Hannakam
	Title:	CEO 5/5/15	 	Title:	Global Head of Marketing and Sales

 

	ACCELERATED PHARMA, INC.	 	HERAEUS PRECIOUS METALS GMBH & Co. KG
	 	 	 	 	 
	By:	/s/ Michael Fonstein	 	By:	/s/ Eberhard Rämisch
	Name:	Michael Fonstein	 	Name:	Eberhard Rämisch
	Title:	CEO 5/5/15	 	Title:	Head of New Sales & Business Development 

        Pharmaceutial Ingredients Business Unit

        Heraeus Precious Metals GmbH & Co. KG

        27.04.2015

 

    	 	Page 10 of 10

     

    

 

Apr.
27th, 15

 

MASTER
SERVICES AGREEMENT

 

Production
of Picoplatin

GMP
Grade

 

Annex
I

Production of 3 GMP-Validation Batches of Picoplatin

 

Including
GMP Documentation and Stability Program

for Regulatory Filing

 

between Accelerated Pharma Inc. with a place
of business at 15W15581 st, Burr Ridge 60527 Illinois, USA ("Accelerated"). and Heraeus Precious Metals GmbH & Co.
KG, a German limited liability company with a principal place of business located at Heraeusstr. 12-14. 63450 Hanau, Germany ("Manufacturer"
or "Heraeus"), each singly a "Party" and together, the "Parties."

 

     

     

    

 

1.        Background, scope and objective

 

Accelerated Pharma Inc. ("Accelerated") is seeking a supplier
for the oncology API Picoplatin. Requirement is expected to be approx. 0.5 kg/year to 1.0 kg/year.

 

Picoplatin is a drug used in cancer chemotherapy and has been manufactured
at Heraeus in the past years in several development campaigns and was validated in 2009 on 2.25 kg scale.

 

The chemical structure and name of Picoplatin is:

 

 

		·	Cis-Rammine)dichloro)(2-methylpyridine)platinum(11)], C61-110C12N2Pt

		·	CAS number: 181630-15-9

		·	CAS name: Platinum. amminedichloro(2-methylpyridine)-, (SP-4-3)-

 

2.        Proposal
Requirements as discussed with Accelerate Pharma Inc.

 

Heraeus has several years of experience in the manufacturing of
Picoplatin. However as the last manufacturing was some years ago, the production process needs to be adapted to the newest standards
as well as Accelerate Pharma Ltd. Inc. specific requirements.

 

This Annex covers the production of Picoplatin drug substance under
cGMP conditions. The target quantity is min. 500g of Picoplatin drug substance per batch. The manufactured drug substance is required
for a clinical development program by Accelerated Pharma

 

The basis of our calculations is the synthetic route followed for
the production of the last Picoplatin cGMP batches 102090070 to 104090070 at Heraeus in 2009. as well as a site change of the manufacturing
plant of the step 3 process. This leads to significant scale and process modifications in step 3 of the process compared to the
batches manufactured in 2009.

 

     

     

    

 

The contract includes:

 

		·	Update of existing cGMP documents prior to manufacture (cleaning records, update of MBRs. (IQ/OQ packages), reflecting process
changes.

 

		·	Preparation of new cGMP documents required for the site change of the step 3 process of Picoplatin drug substance (cleaning
records, update of MBRs, qualification documents due to changed equipment, process change documentation)

 

		·	Required Reference standards for Product and Intermediates

 

		·	Installation and testing of equipment in the laboratory isolator (preparations for steps 1, 2 and 3); programming of the process
control unit, water runs as well as documented calibration of sensors.

 

		·	Production costs as outlined below: step 1 (TCPP). step 2 (Picoplatin Crude) and step 3 (Picoplatin drug substance)

 

		·	Pre-batch cleaning of isolator, cleaning between steps and post-production cleaning

 

		·	Raw materials for syntheses and cleaning, required single-use equipment (inline filters, hoses etc.)

 

		·	Preparation of process documentation after finishing the campaign

 

		·	Quality control for raw materials, intermediates, drug substance and cleaning samples

 

		·	Waste disposal (syntheses and cleaning)

 

		·	Platinum losses and recovery

 

		·	Freight, packing and insurance

 

		·	QA review of all cGMP documents

 

     

     

    

 

3.       Project description 

 

Heraeus has validated the synthesis of Picoplatin on 2.25 kg scale
using the chemical route as outlined below

 

Step1: TCPP

 

 

 

Step 2: Picoplatin Crude

 

 

 

Step 3: Picoplatin

 

 

 

Figure 1: Synthetic route to Picoplatin

 

     

     

    

 

The draft specification for Picoplatin drug substance based on the
last revision of the specification from 2009 is as follows:

 

	Parameter	 	Specification
	1.
        Description

                                                Appearance
	 	A
    yellow powder
	2. Identification
    by IR	 	Conforms
    to reference standard
	3. Identification
    by HPLC	 	Retention time of the picoplatin
    peak in the sample should not differ from that of the reference standard by more than ± 0.2 minutes.
	4. Color of Solution

        
	 	Comparable
        to or between GY2 to GY3 reference solutions (Ph. Eur.)

	5. Clarity of Solution	 	Opalescence must be less than opalescence
                                 reference solution I
                                 (Ph. Eur.)

	6. Picoplatin
    Assay by HPLC	 	98.0- 102.0 `)/0 w/w
	7.
        Impurities by HPLC*

              a)
        2-picoline

              b)
        TCPP

              c)
        TCAP

              d)
        Highest single other impurity

              e)
        Total impurities
	 	 

        NMT
        0.05 % w/w

        NMT 0.2 % w/w

        NMT 0.2 % w/w

        NMT 0.1 % w/w

        NMT 1.0 `)/0 w/w

	8. Residual
        Metals

            Heavy
        Metals

            Process
        Metals

            Iron
	 	

    NMT 20 ppm

    NMT 20 ppm

    NMT 10 ppm
	9 Water
    content (KF)	 	NMT 0.3 % w/w
	10. Residual
    acetone by GC	 	NMTO 5 °A wiw
	11. Endotoxins,
    USP	 	NMT 0.19 EU/mg
	12. Bioburden
    Total aerobic microbial count (TAMC)	 	NMT 10 CFU/g
	13. pH
    of Solution	 	Informative

 

*Impurity profile is not expected
to be changed vs. last production campaigns and no new impurities are expected

 

     

     

    

 

The final specification has to be agreed and
accepted between Accelerated and Heraeus.

 

Stability testing program of the drug substance
to support regulatory filing will be performed

 

Creation
of a Drug Master File and additional other regulatory services are not agreed and included in this quote.

 

Details are described in fcllowing paragraphs.

 

		3.1	Generation of GMP documentation required for process
validation

 

Heraeus will prepare, review and approve all GMP relevant documentation
required to initiate the following GMP production. such as:

 

Validation master plan

Risk analyses

Validation protocols

Equipment qualifica:ion documents

Process documents (batch records,
other SOPs and form sheets)

Cleaning documents (cleaning validation
protocol. cleaning records, other form sheets)

 

Please note:

Responsibilities regarding documentation and approval of documents
and material are described in a separate Quality Agreement.

 

		3.2	Generation of Reference Standards

 

Heraeus will prepare and qualify approx. 300 gram of reference standards
for Picoplatin and sufficient amount of raw materials and intermediates as requested:

 

	Picoplatin	 
	TCPP	 
	2-Picoline	 
	TCAP	(Including CoA)

 

Heraeus will send samples
of reference standards to Accelerated Pharma on request.

 

     

     

    

 

		3..3	Manufacture of Picoplatin GMP Grade

 

Heraeus will manufacture 3 GMP batches of Picoplatin
sequentially on a scale of approx. 500g Picoplatin drug substance in our commercial facility (glove box facility: non-dedicated
glass equipment).

 

- Manufacture
of 3 batches of TCPP, 1 batch Picoplatin Crude and 3 batches of Picoplatin drug substance, including documentation of full
validation of a different batch scale for step 3 and a site change for step 3.

 

Deliveries

Target quantity of gross 3 x approx.
500g Picoplatin drug substance

 

Documentation supplied to Accelerated Pharma Inc.

Certificates of Analysis

Validation protocol / report

Executed batch manufacturing records

 

Timelines

 

A new reactor is already on order for the processing
in step 3 of the synthesis. The lead time of this reactor represents the critical path in the timeline before manufacturing can
start. The generation of the required GMP documentation, sourcing of raw materials and other preparation prior to production will
be performed in this time. Manufacturing will be started as soon as the equipment is installed, raw materials are released and
the required documentation is in place.

 

Details see separate Gant Charts

 

Storage conditions: 25°C based on the existing stability
data for Picoplatin.

 

Currently Heraeus assumes that no amendment in the Heraeus manufacturing
license is required at this stage and an eventual approval by German authorities is not included in the timeline.

 

		3.4	Stability study

 

Heraeus will perform a stability study
on each batch of drug substance manufactured. Conditions for labeled storage set to ambient (25 °C +/- 3 °C; 60% r.H.)
conditions, conditions for accelerated storage set to 40 °C +1- 3 °C; 75% r.H.

 

Testing intervals for each validation batch could be

Labeled conditions: 3, 6, 9. 12, 18. 24, 36,
48, 60 months

Accelerated conditions: 1, 2, 3, 6 months

 

     

     

    

 

4.        Regulatory
services

 

At any time before
successful completion of the work described in sections 3.1 — 3.3. Accelerated and Heraeus should discuss details of the
preparation of required regulatory documentation for Picoplatin.

 

Heraeus offers a professional lifecycle management in
all regions of the world, depending on our clients' needs.

 

Details on required regulatory documentation should be
agreed upon between Accelerated and Heraeus.

 

5.        Limitations
and options

 

Heraeus
does not provide any warranty with regards to Intellectual Property and assumes that Accelerated is fully responsible for FTO and/or
holds IP with regards to active substance and the agreed upon manufacturing processes.

 

Accelerated Ltd. Inc. has to indemnify Heraeus against
third party claims if the manufacturing process and/or the active substance actually or allegedly infringe third party IF rights.

 

6.        Project
management

 

Heraeus will provide an experienced
project manager as technical responsible person throughout the project with either a chemical (Ph.D.) or chemical engineering background.

 

We will work closely
with Accelerated Inc. to assure prompt reporting of the current project status and progress made. Regular project up-dates as well
as option for regular tele or video conferences are standard offers to Heraeus clients.

 

Costs for project management are included in this quotation.

 

7.
       Prices

 

		3.1	Generation of GMP documentation required for process
validation

 

		Price:	USD 70 000 lump sum

 

     

     

    

 

		3.2	Generation of Reference standards

 

		Price:	USD 32 500 lump sum

 

Price for external delivery of Picoplatin reference standard:

 

		 	USD 100 per gram

		 	+ price of Platinum s. 3.2

 

		3..3	Manufacture of GMP Material

 

Our main target is to offer competitive and transparent
prices, therefore we usually mention the Platinum prices and manufacturing prices separately for our APIs

 

While the manufacturing price stays the same for comparable
deliveries, the Platinum price may change over time due to its high volatility.

 

Internal policies ensure that a
booking of Platinum is only possible with a valid PO, therefore we ask for your understanding that we can fix the final prices
only after receipt of the same.

 

Manufacture of three validation
batches of Picoplatin

 

		Price:	USD 350 000 lump sum

 

		 	+ Platinum ca. 250 gr                  approx. USD 30. 000

		 	(40, 50 USD/gram as of April 1st, 2015)

 

		3.4	Stability study

 

		Price:	USD 2450 per test point and temperature

 

		4.	Regulatory services

 

Additional regulatory services are not agreed / included Current
yields and cost estimations are based on the experience Heraeus gathered during the last Picoplatin manufacturing campaign in
2009.

 

In case the place of delivery requested by Accelerated should be
within the European Union, 19% Value Added Tax may apply to invoices regarding delivery within EU. While VAT can be reclaimed by
Accelerated, we suggest to jointly discuss this topic asap prior to order confirmation by Heraeus.

 

     

     

    

 

9.        Terms and conditions

 

Delivery conditions: CIP place of delivery (lncoterms
2010). incl. packing and insurance Payment terms:

 

9.1     100 000 USD, 10 days net from
submission of PO

 

9.2     125 000 USD, net immediately
at start of first batch production

   + Price for Platinum approx. 40,50 USD
per gram

 

9.3     127 500 USD, 10 days net
after finalization of third batch

 

9.4     100 000 USD, 10 days
net after delivery of CoA and Documentation

 

9.5     Stability program:

 

   at/for each time point 10 days net after
submission of CoA/Report

 

Price for Platinum non binding without obligation
until receipt of final PO

 

10.      Outlook on the cost of
commercial production

 

Commercial pricing is driven by the final needs of Accelerated Inc.
(e.g. batch size, choice of manufacturing site).

 

For commercial product supply a license by the German authorities
is mandatory. Current lead time around 6-9 months.

 

This shall be discussed at an appropriate point in time during the
project.

 

11.      Validity of
Pricing

 

The prices offered for items 3.1 - 3.4 and price indications provided
for items 4, 5 and 10 are based on the current EUR/USD exchange rate of 1.10

 

Should the EUR/USD rate at submission of Accelerated's PO for each
of the offered items be outside a range of 1.05-1.15 we will adjust our prices accordingly.

 

12.      Remarks 

 

Availability of plant capacity is subject to a written
agreement.

 

Heraeus will perform all above mentioned work
according to the existing information and will make best efforts to synthesize the required quantities of Picoplatin and
meeting the target specification.

 

     

     

    

 

Should the procedures fail to give the anticipated products or target
quantities, the project scope and costs need to be revised.

 

IN WITNESSETH WHEREOF, the Parties have executed this Agreement
as of the Effective Date.

 

	ACCELERATED
    PHARMA, INC.	 	HERAEUS
PRECIOUS METALS GMBH & CO. KG
	 	 	 	 	 
	By:	Michael Fonstein	 	By:	Eberhard Ramisch
	Title:	CEO	 	Title:	Head of New Sales and Business DevelopmentAMENDMENT NO. 4 TO RECEIVABLES FINANCING AGREEMENT

 

This AMENDMENT NO. 4 TO RECEIVABLES FINANCING AGREEMENT (this “Amendment No. 4”), dated as of October 28, 2016, is by and among VOLT FUNDING CORP. (“Volt Funding”), as borrower (the “Borrower”), the Persons from time to time party hereto as Lenders and LC Participants, PNC BANK, NATIONAL ASSOCIATION (“PNC”), as LC Bank, as an LC Participant, as a Lender and as Administrative Agent, and VOLT INFORMATION SCIENCES, INC. (“Volt”), as initial servicer (the “Servicer”).

 

BACKGROUND

 

WHEREAS, the parties hereto entered into the Receivables Financing Agreement as of July 30, 2015 (as amended, restated, supplemented or otherwise modified through the date hereof, the “Receivables Financing Agreement”); and

 

WHEREAS, the parties hereto wish to amend the Receivables Financing Agreement pursuant to the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

SECTION 1.     Definitions.  Capitalized terms used but not defined in this Amendment No. 4 shall have the meanings assigned to them in the Receivables Financing Agreement.

 

SECTION 2.     Amendments to Receivables Financing Agreement.  Effective as of the date hereof and subject to the satisfaction of the conditions precedent set forth in Section 3 hereof, the Receivables Financing Agreement is hereby amended as follows:

 

(a)           The definition of “Maintech Transaction” set forth in Section 1.01 of the Receivables Financing Agreement pursuant to that certain Amendment No. 2 to Receivables Financing Agreement, dated as of July 29, 2016 (the “Amendment 2 to RFA”), is hereby deleted in its entirety and replaced with the following:

 

“Maintech Transaction” means (i) the sale of all or substantially all of the assets of Maintech, Incorporated, or (ii) the sale of all of the Capital Stock of Maintech, Incorporated, in each case, by the Parent to any Person (other than any Affiliate or Subsidiary of the Parent) and the receipt of the cash proceeds of such sale.

 

(b)           Section 8.04 of the Receivables Financing Agreement, as amended by that certain Amendment 2 to RFA, is hereby deleted in its entirety and replaced with the following:

 

SECTION 8.04.  Financial and Restrictive Covenants.

 

(a)           Prohibition of Share Buybacks or Dividends.  The Parent shall not, at any time, (i) redeem, retire, purchase or acquire any of its Capital Stock, or agree, become or remain liable to do any of the foregoing, nor (ii) make or pay, or agree to become or remain liable to make or pay, any dividend or other distribution of any nature (whether in cash, property, securities or otherwise) on account of or in respect of its Capital Stock, or on account of the purchase, redemption, retirement or acquisition of such Capital Stock.

 

  

  

  

 

(b)           Liquidity Level.  The Parent shall provide to the Administrative Agent a written report in the form attached hereto as Exhibit J (any such report, a “Liquidity Report”) on each Liquidity Report Date.  The Liquidity Report shall reflect the Liquidity Level of the Parent and its Subsidiaries as of the last Business Day of the week immediately preceding the applicable Liquidity Report Date.  The Parent and its Subsidiaries on a consolidated basis shall not permit, on any Liquidity Report Date, the Liquidity Level to be less than the amount set forth in Schedule IV.

 

(c)           Schedule IV to the Receivables Financing Agreement is hereby deleted and replaced in its entirety with the schedule set forth in Exhibit A attached hereto.

 

SECTION 3.     Conditions Precedent.  The effectiveness of this Amendment No. 4 is subject to the satisfaction of all of the following conditions precedent:

 

(a)           The Administrative Agent shall have received a fully executed counterpart of this Amendment No. 4 and the Second Amended and Restated Amendment Fee Letter, dated as of the date hereof, by and among PNC as the Administrative Agent, a Lender, the LC Bank, and an LC Participant, PNC Capital Markets LLC and the Borrower (collectively, the “Amendment No. 4 Documents”).

 

(b)           The Administrative Agent shall have received such documents and certificates as the Administrative Agent shall have reasonably requested on or prior to the date hereof.

 

(c)           The Administrative Agent shall have received all fees and other amounts due and payable to it under the Receivables Financing Agreement and in connection with the Amendment No. 4 Documents on or prior to the date hereof, including, to the extent invoiced, payment or reimbursement of all fees and expenses (including reasonable and documented out-of-pocket fees, charges and disbursements of counsel) required to be paid or reimbursed on or prior to the date hereof.  To the extent such fees and other amounts have not yet been invoiced, the Borrower agrees to remit payment to the applicable party promptly upon receipt of such invoice.

 

(d)           No Event of Default or Unmatured Event of Default, as set forth in Section 10.01 of the Receivables Financing Agreement, shall have occurred and be continuing.

 

SECTION 4.      Amendment.  The Borrower, PNC as the LC Bank, an LC Participant, a Lender, and the Administrative Agent, and the Servicer, hereby agree that the provisions and effectiveness of this Amendment No. 4 shall apply to the Receivables Financing Agreement as of the date hereof.  Except as amended by this Amendment No. 4 and any prior amendments, the Receivables Financing Agreement remains unchanged and in full force and effect.  This Amendment No. 4 is a Transaction Document.

 

  

2

  

 

SECTION 5.     Counterparts.  This Amendment No. 4 may be executed in any number of counterparts, each of which when so executed shall be deemed an original and all of which when taken together shall constitute one and the same agreement.  Delivery of an executed counterpart hereof by facsimile or other electronic means shall be equally effective as delivery of an originally executed counterpart.

 

SECTION 6.     Captions.  The headings of the Sections of this Amendment No. 4 are provided solely for convenience of reference and shall not modify, define, expand or limit any of the terms or provisions of this Amendment No. 4.

 

SECTION 7.     Successors and permitted assigns.  The terms of this Amendment No. 4 shall be binding upon, and shall inure to the benefit of the Borrower, PNC as the LC Bank, an LC Participant, a Lender, and the Administrative Agent, and the Servicer, and their respective successors and permitted assigns.

 

SECTION 8.     Severability.  Any provision of this Amendment No. 4 which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

SECTION 9.     Governing Law and Jurisdiction.  The provisions of the Receivables Financing Agreement with respect to governing law, jurisdiction, and agent for service of process are incorporated in this Amendment No. 4 by reference as if such provisions were set forth herein.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

  

3

  

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 4 by their duly authorized officers as of the date first above written.

 

	 	
VOLT FUNDING CORP.,

as the Borrower

	 
	 	 	 
	 	 	 	 
	
 

	
By: 

	 /s/ Bryan Berndt	 
	 	Name:	
Bryan Berndt

	 
	 	Title:	
Controller

	 
	 	 	 	 

 

	 	

VOLT INFORMATION SCIENCES, INC.,

as the Servicer

	 
	 	 	 
	 	 	 	 
	
 

	
By: 

	 /s/ Bryan Berndt	 
	 	Name:	
Bryan Berndt

	 
	 	Title:	
Controller and Chief Accounting Officer

	 
	 	 	 	 

 

 

Amendment 4 to RFA (PNC/Volt)

  

S-1

  

 

	 	

PNC BANK, NATIONAL ASSOCIATION,

as Administrative Agent

	 
	 	 	 
	 	 	 	 
	
 

	
By: 

	 /s/ Eric Bruno	 
	 	Name:	
Eric Bruno

	 
	 	Title:	
Senior Vice President

	 
	 	 	 	 

                          

	 	

PNC BANK, NATIONAL ASSOCIATION,

as LC Bank and as an LC Participant

	 
	 	 	 
	 	 	 	 
	
 

	
By: 

	 /s/ Eric Bruno	 
	 	Name:	
Eric Bruno

	 
	 	Title:	
Senior Vice President

	 
	 	 	 	 

     

	 	

PNC BANK, NATIONAL ASSOCIATION,

as a Lender

	 
	 	 	 
	 	 	 	 
	
 

	
By: 

	 /s/ Eric Bruno	 
	 	Name:	
Eric Bruno

	 
	 	Title:	
Senior Vice President

	 
	 	 	 	 

 

 

 

 

Amendment 4 to RFA (PNC/Volt)

  

S-2

  

 

Exhibit A to Amendment 4 to RFA

 

SCHEDULE IV

Financial Covenant

 

Financial Covenant Definitions.

 

“Liquidity Level” means, at any referenced time, an amount equal to the sum of the (a) aggregate available amount to the Borrower under and pursuant to the terms of this Agreement, (b) the value of all unmatured Marketable Securities held by the Parent and its consolidated Subsidiaries and (c) unrestricted cash and cash equivalents (per bank ledger balance) on hand at such time, as determined for the Parent and its consolidated Subsidiaries on a consolidated basis; provided, however, that beginning on August 1, 2016 and at all times thereafter, at least 50% of the domestic unrestricted cash and cash equivalents (per bank ledger balance) must be on deposit in accounts maintained by one or more of the Parent and its Subsidiaries at PNC.  For the avoidance of doubt: (x) at all times the respective depositors shall have free and unencumbered access to such domestic unrestricted cash and cash equivalents (per bank ledger balance) in such respective accounts maintained at PNC; and (y) without limiting the generality of the foregoing, in no event shall any such cash and cash equivalents (per bank ledger balance) in any such account be subject to any setoff, appropriation or application except in accordance with any applicable Transaction Document and only against amounts (if any) then owing by such respective depositor to PNC.

 

Financial Covenant Thresholds.

 

Liquidity Level Amount.  For the purposes of Section 8.04(b) the amount referred to therein is as set forth in the chart below:

 

	
Time Period

	
Liquidity Level Amount1

	
Closing Date to January 30, 2016

	$20,000,000
	
January 31, 2016 and thereafter

	$35,000,000

 

 

 

 1 If the Maintech Transaction has occurred, from the date of the Maintech Transaction and thereafter, the Liquidity Level Amount shall be an amount equal to Forty Million Dollars ($40,000,000).  If the Maintech Transaction has not occurred, the Liquidity Level Amounts as reflected in the chart above shall remain unchanged.

 

 

 

 

 

  Ex. A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]